Research Topics
| Leo LuznikSummaryAffiliation: Johns Hopkins University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantationLeo Luznik
Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
Semin Oncol 39:683-93. 2012..This review discusses the history of HLA-haploidentical SCT, recent clinical results, and immunologic mechanisms of action of high-dose PT/Cy for prevention of graft rejection and GVHD...
High-dose cyclophosphamide for graft-versus-host disease preventionLeo Luznik
Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21231, USA
Curr Opin Hematol 17:493-9. 2010..This strategy has recently been adapted to human transplantation...
Nonmyeloablative alternative donor transplantsLeo Luznik
Divisions of Hematologic Malignancies and Immunology Hematopoiesis, Johns Hopkins Oncology Center, Baltimore, Maryland, USA
Curr Opin Oncol 15:121-6. 2003..Early clinical results suggest that the use of alternative donors is feasible, therefore potentially allowing full extension of the benefits of allografting to the group of patients in highest need...- High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host diseaseLeo Luznik
Sidney Kimmel Comprehensive Cancer Center and Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
Blood 115:3224-30. 2010..These results suggest that high-dose posttransplantation cyclophosphamide is an effective single-agent prophylaxis of acute and chronic GVHD after BuCy conditioning and HLA-matched BMT (clinicaltrials.gov no. NCT00134017)... - Finding the best way to train the immune system against lymphomaLeo Luznik
Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD 21231-1000, USA
Leuk Lymphoma 47:577-9. 2006 - HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamideLeo Luznik
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
Biol Blood Marrow Transplant 14:641-50. 2008..02). Nonmyeloablative HLA-haploidentical BMT with posttransplantation Cy is associated with acceptable rates of fatal graft failure and severe aGVHD or cGVHD... - Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcomeYvette L Kasamon
Johns Hopkins University, 1650 Orleans Street, Baltimore, MD 21231, USA
Biol Blood Marrow Transplant 16:482-9. 2010..55, P = .03 for 3-4 vs fewer allele mismatches). Thus, greater HLA disparity does not appear to worsen overall outcome after NMA haploidentical BMT with high-dose posttransplantation cyclophosphamide... - Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouseNadira Durakovic
Divisions of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
Blood 109:4564-74. 2007.... - HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell diseaseJavier Bolaños-Meade
Hematologic Malignancies and Bone Marrow Transplantation Program, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and Johns Hopkins University School of Medicine, Baltimore, MD 21231 1000, USA
Blood 120:4285-91. 2012..Graft failure, 43% in haploidentical pairs, remains a major obstacle but may be acceptable in a fraction of patients if the majority can be cured without serious toxicities... - Rapamycin promotes emergence of IL-10-secreting donor lymphocyte infusion-derived T cells without compromising their graft-versus-leukemia reactivityNadira Durakovic
Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
Transplantation 83:631-40. 2007..There are limited data examining the effects of pharmacological immunosuppression on the in vivo fate of donor lymphocyte infusions (DLI)-derived T cells, their function, and their antitumor efficacy... - Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromesErica D Warlick
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States
Leuk Res 32:1439-47. 2008..These results suggest that it is possible to maintain treatment intensity while minimizing toxicity in older, high-risk MDS patients... - Successful therapy of metastatic cancer using tumor vaccines in mixed allogeneic bone marrow chimerasLeo Luznik
Divisions of Hematopoiesis/Immunology and Hematologic Malignancies, Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, MD, USA
Blood 101:1645-52. 2003.... - 5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantationJavier Bolaños-Meade
George W Santos Bone Marrow Transplant Service, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
Biol Blood Marrow Transplant 17:754-8. 2011..5 days (127-1411). These results further suggest that 5-azacytidine is an active agent after failing an allogeneic bone marrow transplant, and prospective studies are warranted... - Induction of autologous graft-versus-host disease: results of a randomized prospective clinical trial in patients with poor risk lymphomaJavier Bolaños-Meade
George W Santos Bone Marrow Transplant Service, Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
Biol Blood Marrow Transplant 13:1185-91. 2007..The administration of oral cyclosporine followed by interleukin-2 and gamma-interferon is generally not well tolerated, and does not appear to be an effective method to induce autologous GVHD in patients receiving autologous PBSC grafts... - High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomasDouglas E Gladstone
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21287, USA
Leuk Lymphoma 52:2076-81. 2011..The 5-year EFS and OS for patients with MCL were 39% and 62%, respectively. This low-toxicity therapeutic approach obviates the need for stem cell products and establishes a platform for future therapies... - High-dose cyclophosphamide for severe aplastic anemia: long-term follow-upRobert A Brodsky
Division of Hematology, Department of Medicine, Johns Hopkins University School ofMedicine, 720 Rutland Ave, Ross Bldg, Rm 1025, Baltimore, MD 21205, USA
Blood 115:2136-41. 2010.... - Graft-versus-host reactions and the effectiveness of donor lymphocyte infusionsCarol Ann Huff
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, MD 21231, USA
Biol Blood Marrow Transplant 12:414-21. 2006..However, with the exception of CML, most patients die of their underlying disease because of insufficient antitumor activity even with active GVHD... - The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cellsHeather J Symons
Division of Cancer Immunology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
Biol Blood Marrow Transplant 14:499-509. 2008..These events provide the cellular mechanism of the "allogeneic effect" in antitumor immunity. Cy + CD8(-) DLI may be an effective and minimally toxic strategy for awakening the host immune response to advanced cancers... - Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell eliminationVedran Radojcic
Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Cancer Immunol Immunother 59:137-48. 2010.... - Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantationLeo Luznik
Divisions of Hematologic Malignancies and Immunology Hematopoiesis, Johns Hopkins Oncology Center, Baltimore, MD 21231, USA
Cancer Control 9:123-37. 2002..Patients with hematologic malignancies in relapse after allogeneic bone marrow transplantation can be treated by infusing leukocytes from the original stem cell donor... - High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantationLeo Luznik
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 288 Bunting Blaustein Cancer Research Building, Baltimore, MD 21231, USA
Immunol Res 47:65-77. 2010..By reducing the morbidity and mortality of alloHSCT, post-transplantation Cy may expand the applications of this therapy to the treatment of autoimmune diseases and non-malignant hematologic disorders such as sickle cell disease... - Host-derived Langerhans cells persist after MHC-matched allografting independent of donor T cells and critically influence the alloresponses mediated by donor lymphocyte infusionsNadira Durakovic
Divisions of Hematologic Malignancies and Cancer Immunology and Hematopoiesis, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Baltimore, MD 21231, USA
J Immunol 177:4414-25. 2006.... - Partially mismatched transplantation and human leukocyte antigen donor-specific antibodiesDouglas E Gladstone
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, Baltimore, MD 21287, USA
Biol Blood Marrow Transplant 19:647-52. 2013.... - STAT3 signaling in CD4+ T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine modelVedran Radojcic
Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
J Immunol 184:764-74. 2010.... - Role of allogeneic transplantation for FLT3/ITD acute myeloid leukemia: outcomes from 133 consecutive newly diagnosed patients from a single institutionAmy E Dezern
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
Biol Blood Marrow Transplant 17:1404-9. 2011..Our single-institution study of consecutively treated AML patients supports the hypothesis that allogeneic transplant in early CR1 improves the long-term outcomes for FLT3/ITD AML... - Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphomaJennifer A Kanakry
Department of Oncology, Johns Hopkins University, Baltimore, Maryland
Biol Blood Marrow Transplant 19:602-6. 2013..AlloBMT may be appropriate in first remission in select high-risk cases... - Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamideAshley Munchel
Divisions of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
Pediatr Rep 3:e15. 2011..These outcomes suggest that mini-haploBMT with post-transplantation Cy is associated with acceptably low toxicities and can provide longterm survival, if not cure, for many patients with advanced hematologic malignancies... - Early lymphocyte recovery after intensive timed sequential chemotherapy for acute myelogenous leukemia: peripheral oligoclonal expansion of regulatory T cellsChristopher G Kanakry
Division of Hematologic Malignancies, The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
Blood 117:608-17. 2011..Further insight into this oligoclonal regulatory T-cell population will be fundamental toward developing effective immunomodulatory techniques to improve survival for patients with AML... - New treatment approaches in acute myeloid leukemia: review of recent clinical studiesKelly Norsworthy
University of Maryland, Department of Medicine, Baltimore, MD 21287 0013, USA
Rev Recent Clin Trials 7:224-37. 2012..We will review here recent clinical studies that examined novel pharmacologic and immunologic approaches to AML therapy... - Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiationLeo Luznik
Division of Immunology/Hematopoiesis, Johns Hopkins Oncology Center, Baltimore, Maryland, USA
Biol Blood Marrow Transplant 8:131-8. 2002..These data demonstrate that low-dose TBI and posttransplantation Cy cooperate to prevent graft rejection following the transplantation of standard doses of MHC-identical marrow cells... - Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302Javier Bolaños-Meade
Hematologic Malignancies, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
Biol Blood Marrow Transplant 19:481-5. 2013..We found no significant differences in lymphocyte total or subpopulation counts among the 4 treatment arms, and no notable influence on outcomes...
Research Grants
- Augmenting Antitumor Immunity after AllograftingLeo Luznik; Fiscal Year: 2009....
- Augmenting Antitumor Immunity after AllograftingLeo Luznik; Fiscal Year: 2010....